502496-21-1 Usage
General Description
4-Fluoro-2-(trifluoromethyl)phenylhydrazine(HCl) is a chemical compound that contains a phenyl ring with a fluorine and trifluoromethyl group attached to it, as well as a hydrazine functional group. It is commonly found in the form of its hydrochloride salt. 4-Fluoro-2-(trifluoromethyl)phenylhydrazine(HCl) is used in organic synthesis as a reagent for the preparation of various pharmaceutical and agrochemical compounds. It is also utilized as a building block in the synthesis of organic materials. Additionally, 4-Fluoro-2-(trifluoromethyl)phenylhydrazine(HCl) has been studied for its potential pharmacological properties, including its antibacterial and antifungal activities. However, it is important to handle this chemical with care as it may be hazardous if not properly handled and stored.
Check Digit Verification of cas no
The CAS Registry Mumber 502496-21-1 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 5,0,2,4,9 and 6 respectively; the second part has 2 digits, 2 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 502496-21:
(8*5)+(7*0)+(6*2)+(5*4)+(4*9)+(3*6)+(2*2)+(1*1)=131
131 % 10 = 1
So 502496-21-1 is a valid CAS Registry Number.
InChI:InChI:1S/C7H6F4N2.ClH/c8-4-1-2-6(13-12)5(3-4)7(9,10)11;/h1-3,13H,12H2;1H
502496-21-1Relevant articles and documents
Substituted tetrahydro-1H-pyrido[4,3-b]indoles as serotonin receptors agonists and antagonists
-
Page/Page column 23, (2010/11/25)
The present application describes compounds, including all pharmaceutically acceptable salts, prodrugs, solvates and stereoisomers thereof, according to Formula I, pharmaceutical compositions, comprising at least one compound according to Formula I and optionally at least one additional therapeutic agent and methods of treating various diseases, conditions and disorders associated with modulation of serotonin receptors such as, for example: metabolic diseases, which includes but is not limited to obesity, diabetes, diabetic complications, atherosclerosis, impared glucose tolerance and dyslipidemia; central nervous system diseases which includes but is not limited to, anxiety, depression, obsessive compulsive disorder, panic disorder, psychosis, schizophrenia, sleep disorder, sexual disorder and social phobias; cephalic pain; migraine; and gastrointestinal disorders using compounds according to Formula I
